http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 15:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++REGENTIS+BIOMATERIALS++++++++++++++++++Filed+by%3A+REGENTIS+BIOMATERIALS+LTD./26574432.html si-local-file:///var/storage/secattach/20260529/26574432.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++REGENTIS+BIOMATERIALS++++++++++++++++++Filed+by%3A+REGENTIS+BIOMATERIALS+LTD./26574432.html Fri, 29 May 2026 15:23:00 -0400 O.13817872 RGNT http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++REGENTIS+BIOMATERIALS++++++++++++++++++Filed+by%3A+REGENTIS+BIOMATERIALS+LTD./26574432.html si-local-file:///var/storage/secattach/20260529/26574432.html http://www.streetinsider.com/SEC+Filings/Form++FWP++++++++REGENTIS+BIOMATERIALS++++++++++++++++++Filed+by%3A+REGENTIS+BIOMATERIALS+LTD./26574432.html Fri, 29 May 2026 15:23:00 -0400 O.13817872 RGNT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++REGENTIS+BIOMATERIALS+++++For%3A+May+28/26568417.html si-local-file:///var/storage/secattach/20260528/26568417.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++REGENTIS+BIOMATERIALS+++++For%3A+May+28/26568417.html Thu, 28 May 2026 16:45:00 -0400 O.13817872 RGNT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++REGENTIS+BIOMATERIALS+++++For%3A+May+28/26568417.html si-local-file:///var/storage/secattach/20260528/26568417.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++REGENTIS+BIOMATERIALS+++++For%3A+May+28/26568417.html Thu, 28 May 2026 16:45:00 -0400 O.13817872 RGNT http://www.streetinsider.com/New+Coverage/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html <p>ThinkEquity analyst Ashok Kumar initiates coverage on Regentis Biomaterials Ltd. (NYSE: RGNT) with a Buy rating and a price target of $10.00.</p><p>The analyst comments "Regentis Biomaterials is a single-asset medtech advancing GelrinC for focal knee cartilage defects; GelrinV and GelrinP are optionality. We rate the shares BUY with a $10.00 price target because de-risking is underway: Europe has CE Mark approval with a partner-led http://www.streetinsider.com/New+Coverage/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html Mon, 02 Mar 2026 06:29:14 -0400 RGNT http://www.streetinsider.com/Analyst+Comments/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html <p>ThinkEquity analyst Ashok Kumar initiates coverage on Regentis Biomaterials Ltd. (NYSE: RGNT) with a Buy rating and a price target of $10.00.</p><p>The analyst comments "Regentis Biomaterials is a single-asset medtech advancing GelrinC for focal knee cartilage defects; GelrinV and GelrinP are optionality. We rate the shares BUY with a $10.00 price target because de-risking is underway: Europe has CE Mark approval with a partner-led http://www.streetinsider.com/Analyst+Comments/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html Mon, 02 Mar 2026 06:29:14 -0400 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0400 A.04832063 A.19657706 O.13817872 O.36250936 RGNT